Clene vs Incannex Healthcare
CLNN and IXHL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CLNN and IXHL compare
Clene is the larger company, worth 2.0 times as much as Incannex Healthcare ($50.4M against $24.7M).
Incannex Healthcare scores higher on the StockData Score (7 against 1 for Clene), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CLNN | IXHL |
|---|---|---|
| Size and price | ||
| Market cap | $50.4M | $24.7M |
| Share price | $3.92 | $1.97 |
| Change, 1 year | −58.3% | −82.4% |
| Change, 5 years | −96.1% | – |
| Beta (5Y) | 0.79 | 1.95 |
| Employees | 79 | 12 |
| StockData Score | ||
| Total score | 1 | 7 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 0 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 212× | – |
| P/B | – | 0.4× |
| FCF yield | – | −52.1% |
| Growth | ||
| Revenue growth (TTM) | 11.2% | – |
| Revenue growth, 5Y average | −0.59% | – |
| Profitability | ||
| Gross margin | 68.5% | – |
| Operating margin | −8929% | – |
| Net margin | −11271% | – |
| Return on equity | – | −47.8% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −7.3× | – |
| Current ratio | 0.85 | 48.81 (better) |
| Altman Z-score | −23.07 | −0.62 (better) |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −280% |
| Shareholder yield | 0.00% (better) | −280% |
| Ownership | ||
| Held by institutions | 24.8% | 3.6% |
| Held by insiders | 45.9% | – |
| Insider net buying, 12 months | −$5.6M | – |
| Short interest, % of float | 6.0% | – |
Go deeper
- CLNN stock overview
- CLNN income statement
- CLNN valuation and score
- IXHL stock overview
- IXHL income statement
- IXHL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.